Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 6, 2026, 8:16 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 347 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Aortic Stenosis Clear all
Completed Phase 2 Interventional

Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle

NCT00001960
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Pacemaker therapy
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 6, 2026, 8:16 AM EDT
Completed No phase listed Observational

WS-SAVE Study (Williams Syndrome Skin and Vessel Elasticity Study)

NCT02692846
View directory record Official record
Conditions
Williams Syndrome, Cardiovascular Disease, Multisystem Developmental Disorder, Elastin Gene Deletion, Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
1 Year to 70 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 6, 2026, 8:16 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Exercise Study Including Patients With Hypertrophic Cardiomyopathy

NCT01165749
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
stop exercising
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2010 · Synced Oct 6, 2026, 8:16 AM EDT
Completed Not applicable Interventional

Aortic Valve and Root Measurements Under Real-Time 3-Dimensional Visualization During Angiography

NCT02073617
View directory record Official record
Conditions
Coronary Artery Disease, Aortic Stenosis
Interventions
Real-time 3-dimensional DynaCT
Radiation
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Oct 6, 2026, 8:16 AM EDT
Completed No phase listed Observational

CryoValve® SG Aortic Human Heart Valve Combination Study

NCT01236469
View directory record Official record
Conditions
Aortic Valve Stenosis, Aortic Valve Insufficiency
Interventions
Echocardiogram
Procedure
Lead sponsor
CryoLife, Inc.
Industry
Eligibility
6 Years to 27 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2015 · Synced Oct 6, 2026, 8:16 AM EDT
Recruiting Phase 1Phase 2 Interventional

Multi-center, Open-label, Single-ascending Dose Study of Safety and Tolerability of TN-201 in Adults With Symptomatic MYBPC3 Mutation-associated HCM

NCT05836259
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
TN-201
Genetic
Lead sponsor
Tenaya Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
10
States / cities
La Jolla, California • San Francisco, California • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced Oct 6, 2026, 8:16 AM EDT
Completed No phase listed Observational

Prospective Evaluation of Neurocognition in Patients Undergoing Transcatheter Aortic Valve Replacement

NCT05614986
View directory record Official record
Conditions
Mild Cognitive Impairment, Aortic Stenosis
Interventions
5 minute Montreal Cognitive Assessment (mini MoCA)
Other
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
4
States / cities
Dallas, Texas • Fort Worth, Texas • Plano, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 6, 2026, 8:16 AM EDT
Recruiting No phase listed Observational

Pre-Emptive LAVA-ECMO for Complex High-Risk TAVR

NCT07309029
View directory record Official record
Conditions
Severe Aortic Stenosis, Cardiogenic Shock, Cardiogenic Shock, ECMO, Trans-catheter Aortic Valve Implantation
Interventions
Left Atrial Veno-Arterial Extracorporeal Membrane Oxygenation (LAVA-ECMO)
Device
Lead sponsor
Atlantic Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Detroit, Michigan • Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Oct 6, 2026, 8:16 AM EDT
Not listed No phase listed Observational

Transcatheter Aortic Valve Replacement (TAVR) Double Balloon Valvuloplasty

NCT05189886
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Double Balloon Valvuloplasty in TAVR
Procedure
Lead sponsor
Community Memorial Health System
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jan 13, 2022 · Synced Oct 6, 2026, 8:16 AM EDT
Completed Not applicable Interventional Results available

Aortic Valve Replacement With Trifecta(TM)

NCT00475709
View directory record Official record
Conditions
Aortic Valve Insufficiency, Regurgitation, Aortic Valve, Aortic Valve Incompetence, Aortic Valve Stenosis
Interventions
Trifecta Aortic Heart Valve
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
1,022 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
18
States / cities
Los Angeles, California • Sarasota, Florida • Maywood, Illinois + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2019 · Synced Oct 6, 2026, 8:16 AM EDT
Terminated No phase listed Observational

Non-Contrast Magnetic Resonance Angiography Assessment of Patients Referred for Transcatheter Aortic Valve Implantation

NCT02007967
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Not listed
Lead sponsor
University of Michigan
Other
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 22, 2016 · Synced Oct 6, 2026, 8:16 AM EDT
Completed Phase 4 Interventional Results available

Ranolazine for the Treatment of Chest Pain in HCM Patients

NCT01721967
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Ranolazine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 3, 2017 · Synced Oct 6, 2026, 8:16 AM EDT
Completed No phase listed Observational Results available

Trifecta™ Long Term Follow-Up (LTFU) Study

NCT01593917
View directory record Official record
Conditions
Aortic Valve Insufficiency, Aortic Valve Regurgitation, Aortic Valve Stenosis, Aortic Valve Incompetence
Interventions
Trifecta™ Valve
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
9
States / cities
Los Angeles, California • Minneapolis, Minnesota • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Oct 6, 2026, 8:16 AM EDT
Terminated Not applicable Interventional

A STEP for Patients Prior to Undergoing TAVR: A Pilot Study

NCT02766075
View directory record Official record
Conditions
Frail Elderly, Aortic Valve Stenosis
Interventions
Supervised TAVR Exercise Program
Behavioral
Lead sponsor
OSF Healthcare System
Other
Eligibility
50 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Peoria, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 12, 2018 · Synced Oct 6, 2026, 8:16 AM EDT
Completed Phase 3 Interventional Results available

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

NCT02833948
View directory record Official record
Conditions
Aortic Valve Stenosis, Cardiovascular Diseases, Heart Valve Diseases, Ventricular Outflow Obstruction, Thrombosis
Interventions
Acetylsalicylic acid, Clopidogrel, Rivaroxaban
Drug
Lead sponsor
ECRI bv
Industry
Eligibility
18 Years and older
Enrollment
231 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2020 · Synced Oct 6, 2026, 8:16 AM EDT
Not listed Not applicable Interventional

Electronic Physician Notification to Facilitate the Recognition and Management of Severe Aortic Stenosis: The DETECT AS Trial

NCT05230225
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Physician Notification Letter
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Oct 6, 2026, 8:16 AM EDT
Completed Not applicable Interventional Results available

Aortic or Mitral Valve Replacement With the Biocor and Biocor Supra

NCT00636987
View directory record Official record
Conditions
Aortic Valve Insufficiency, Aortic Valve Regurgitation, Aortic Valve Stenosis, Aortic Valve Incompetence, Mitral Valve Insufficiency, Mitral Valve Regurgitation, Mitral Valve Stenosis, Mitral Valve Incompetence
Interventions
Biocor and Biocor Supra valves
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
17
States / cities
La Jolla, California • Los Angeles, California • Evansville, Indiana + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2019 · Synced Oct 6, 2026, 8:16 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

NCT02291237
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Eleclazine, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
26
States / cities
Los Angeles, California • Stanford, California • New Haven, Connecticut + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Oct 6, 2026, 8:16 AM EDT
Active, not recruiting Not applicable Interventional Results available

Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients

NCT02701283
View directory record Official record
Conditions
Aortic Valve Stenosis
Interventions
Medtronic Transcatheter Aortic Valve Replacement Systems, Surgical Aortic Valve Replacement (SAVR)
Device
Lead sponsor
Medtronic Cardiovascular
Industry
Eligibility
Not listed
Enrollment
2,223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
61
States / cities
Phoenix, Arizona • La Jolla, California • Los Angeles, California + 53 more
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Oct 6, 2026, 8:16 AM EDT
Completed Not applicable Interventional

Point-of-Care Echocardiography in Patients With Known or Suspected Aortic Stenosis

NCT06717373
View directory record Official record
Conditions
Patients With an Indication for an Echocardiographic Examination With Suspicion of Valcular Heart Disease
Interventions
AutoAS
Device
Lead sponsor
Caption Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 6, 2026, 8:16 AM EDT
Completed Phase 1 Interventional

Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B

NCT03882437
View directory record Official record
Conditions
Danon Disease
Interventions
RP-A501
Biological
Lead sponsor
Rocket Pharmaceuticals Inc.
Industry
Eligibility
8 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 6, 2026, 8:16 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of EDG-7500 in Adults With Hypertrophic Cardiomyopathy (CIRRUS-HCM)

NCT06347159
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
EDG-7500
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
21
States / cities
San Francisco, California • Stanford, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 6, 2026, 8:16 AM EDT
Recruiting Phase 2 Interventional

A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis

NCT05646381
View directory record Official record
Conditions
Aortic Stenosis
Interventions
Pelacarsen (TQJ230) 80mg, Matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
50 Years to 80 Years
Enrollment
502 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
35
States / cities
Huntsville, Alabama • Beverly Hills, California • Covina, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 6, 2026, 8:16 AM EDT
Recruiting Phase 4 Interventional

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

NCT07600177
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
Aficamten
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Kansas City, Missouri • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 6, 2026, 8:16 AM EDT